ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0880 • ACR Convergence 2024

    Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis

    Charles Besidonne1, Andrew Benest1, Kim Chisholm1, Jonathan Morris2, Lucy Donaldson3, Jeanette Woolard4 and David Bates1, 1University of Nottingham, Nottingham, United Kingdom, 2University of New South Wales, New South Wales, New South Wales, Australia, 3Versus Arthritis UK, Nottingham, United Kingdom, 4University of Nottingham, Nottingham, England, United Kingdom

    Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…
  • Abstract Number: 0909 • ACR Convergence 2024

    Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…
  • Abstract Number: 0678 • ACR Convergence 2024

    Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually

    Oliver Distler1, Margarida Alves2, Gerrit Toenges3 and Anna-Maria Hoffmann-Vold4, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 4Oslo University Hospital, Oslo, Norway

    Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
  • Abstract Number: 0914 • ACR Convergence 2024

    RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine

    Shailja C. Shah1, Tyler S. Reese2, Laura L. Daniel3, Puran Nepal4, Jacy Zanussi3, Alyson L. Dickson2, Ran Tao2, Adriana M. Hung5, Wei-Qi Wei2, C. Michael Stein2, QiPing Feng2 and Cecilia P. Chung3, 1University of California, San Diego, San Diego, CA, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Miami, Miami, FL, 4Vanderbilt University Medical Center, Vanderbilt, TN, 5Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Pancreatitis is a rare, but potentially life-threatening adverse event associated with the use of azathioprine. Prior studies have found an association between the HLA…
  • Abstract Number: 0425 • ACR Convergence 2024

    Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases

    Antia Garcia Fernandez1, Fernando Rengifo-Garcia1, Raquel Senosiain-Echarte1, Miguel Álvaro Navidad1, Miguel Angel Gonzalez-Gay2 and Juan Antonio Martínez - López1, 1Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 2University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain

    Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…
  • Abstract Number: 0449 • ACR Convergence 2024

    Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects

    Ana Cecilia Bardan-Inchaustegui1, Iris Jazmín Colunga Pedraza2, Rosa Icela Arvizu-Rivera2, Gisela Garcia-Arellano3, Griselda Serna-Peña4, Maria F. Elizondo-Benitez5, Aleydis Gonzalez Melendez2, Fernanda Massiel Garcia6 and Dionicio Galarza-Delgado7, 1Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, 5Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 6Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
  • Abstract Number: 0695 • ACR Convergence 2024

    Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort

    Stefano Di Donato1, Marco Minerba2, Enrico De Lorenzis3, Collette Hartley4, Lesley-Anne Bissell5, Rebecca Ross6 and Francesco Del Galdo4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Campus Bio-Medico University of Rome, Taranto, United Kingdom, 3Catholic University of the Sacred Heart, Roma, Rome, Italy, 4University of Leeds, Leeds, United Kingdom, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
  • Abstract Number: 0829 • ACR Convergence 2024

    Epstein-Barr Virus Infection Triggers Hyperinflammation and Cytokine Storm in Healthy Children

    Kailey Brodeur1, Meng Liu2, Rachel Weng2, Evan Hsu2, Lauren Henderson3, Fatma Dedeoglu2, Jane Newburger3, Peter Nigrovic4, Mary Beth Son4 and Pui Lee5, 1Boston Children's Hospital, Cumberland, RI, 2Boston Children's Hospital, Boston, MA, 3Boston Children's Hospital, Watertown, MA, 4Boston Children's Hospital, Brookline, MA, 5Boston Children's Hospital, Newton, MA

    Background/Purpose: Epstein-Barr virus (EBV) is common pathogen responsible for infectious mononucleosis but also triggers hemophagocytic lymphohistiocytosis (HLH). This variation in the immune response to EBV…
  • Abstract Number: 0439 • ACR Convergence 2024

    Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

    Laura Kobashigawa1, Cassidy Hernandez-Tamayo2, Katherine Ruddy3, Melissa Wilson2 and Leanna Wise4, 1University of Southern California/Los Angeles General Medical Center, Pasadena, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, 4LAC+USC/Keck Medicine of USC, Pasadena, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
  • Abstract Number: 0889 • ACR Convergence 2024

    Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics

    Tomás Gomes1, Matilde Bandeira2, Rui do Amaral Vieira1, Bianca Correia1, Sofia Barreira3, Pedro Gaspar4, Rita Cruz-Machado5, Beatriz Filipe1, Pedro Ávila-Ribeiro1, Filipa Ribeiro1, Bruno Vidal1, Beatriz Val1, Filipa Costa6, Ana Teodósio Chícharo7, Augusto Silva1, Manuel Silvério-Antonio1, João Forjaz Lacerda1, João Eurico Fonseca1, Dolores López Presa8, Nikita Khmelinskii1, Saumya Kumar9, Luis Graca1 and Vasco C. Romão10, 1Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, 2Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, 3Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, 4Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, 5Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, 6Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, 7Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, 8Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, 9TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, 10Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

    Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
  • Abstract Number: 0908 • ACR Convergence 2024

    Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci

    Nina Oparina1, Sarah Reid2, Ahmed Sayadi3, Maija-Leena Eloranta4, Martina Frodlund5, Karoline Lerang6, Andreas Jönsen7, Solbritt Rantapaa-Dahlqvist8, Anders Bengtsson7, Anna Rudin9, Øyvind Molberg10, Christopher Sjowall11, Lars Rönnblom4 and Dag Leonard4, 1UU, Uppsala, Sweden, 2Uppsala University, Medical Sciences, Uppsala, Sweden, 3Uppsala, Uppsala, Sweden, 4Uppsala University, Uppsala, Sweden, 5Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 6Oslo University, Oslo, Norway, 7Lund University, Lund, Sweden, 8Umeå University, Umeå, Sweden, 9Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 10Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 11Linköping University, Linköping, Sweden

    Background/Purpose: Heritability of SLE is high and more than 200 genetically associated SLE risk loci were identified. Part of them  are specific and associate with…
  • Abstract Number: 0916 • ACR Convergence 2024

    Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia

    Mahmut Kaymakci1, Anuya Natu2, Clifford Csizmar2, Terra Lasho2, Christy Finke2, Abhishek Mangaonkar1, Aref Al-Kali1, Hassan Alkhateeb1, Jenna Fernandez2, Matthew Koster1, Cornelia Weyand2, Mrinal Patnaik1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester

    Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
  • Abstract Number: 0818 • ACR Convergence 2024

    Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration

    Stylianos Georgiadis1, Lykke Oernbjerg1, Brigitte Michelsen2, Tore K. Kvien3, Simon Horskjær Rasmussen4, Jakub Závada5, Kristýna Bubová6, Bente Glintborg7, Anne Gitte Loft8, Ana Maria Rodrigues9, Maria Jose Santos10, Adrian Ciurea11, Michael Nissen12, Laura Kuusalo13, Jarno Rutanen14, Ziga Rotar15, Katja Perdan-Pikmajer15, Bjorn Gudbjornsson16, Olafur Palsson17, Daniela DiGuiseppe18, Mikkel Ostergaard19 and Merete Hetland20, 1Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, 2Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, 3Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Rigshospitalet Glostrup, Glostrup, Denmark, 5Institute of Rheumatology and Charles University, Praha, Czech Republic, 6Institute of Rheumatology and Charles University, Prague, Czech Republic, 7DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, 8Aarhus University Hospital and Aarhus University, Horsens, Denmark, 9Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, 10Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, 11University Hospital Zurich, Zürich, Switzerland, 12Geneva University Hospital, Geneva, Switzerland, 13University of Turku and Turku University Hospital, Turku, Finland, 14Tampere University Hospital, Tampere, Finland, 15University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 16Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 17University of Iceland and Skåne University Hospital, Reykjavik, Iceland, 18Karolinska Institutet, Stockholm, 19Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 20Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark

    Background/Purpose: While the Axial Spondyloarthritis Disease Activity Score based on C-reactive protein (ASDAS) is recommended for assessment of disease activity in patients with axial spondyloarthritis…
  • Abstract Number: 0733 • ACR Convergence 2024

    Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)

    Sai Shanmukha Sreeram Pannala1, fares Saliba2, Medha Rajamanuri3 and Veena Katikineni4, 1Staten Island University Hospital, Northwell Health, staten island, new york city, NY, 2Staten Island University Hospital, Staten Island, NY, 3Southern Illinois University School of Medicine, Springfield, IL, 4Providence, Victorville, CA

    Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…
  • Abstract Number: 0467 • ACR Convergence 2024

    Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort

    FROIDURE Antoine1, DOYEN Marie2, PERROT Marie1, GHAYE Benoit3, SAPART Emilie4, BEARZATTO Bertrand5, DURANT Jean-François5, AMBROISE Jérôme5, GALA Jean-Luc5, ZAN Deniz3, AVRAMOVSKA Aleksandra4, SOKOLOVA Tatiana4, KOENIG Sandra2 and DUREZ Patrick4, 1Pulmonology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Radiology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 5Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium

    Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…
  • « Previous Page
  • 1
  • …
  • 361
  • 362
  • 363
  • 364
  • 365
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology